Evidence map›Paper›PMID 34830507›Full record

ArticleJournal of clinical medicine2021

Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland.

Agata Czarnowska, Katarzyna Kapica-Topczewska, Olga Zajkowska, Monika Adamczyk-Sowa, Katarzyna Kubicka-Bączyk, Natalia Niedziela, Paweł Warmus, Alicja Kalinowska-Łyszczarz, Karolina Kania, Agnieszka Słowik and 28 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Global prevalence of post-COVID-19 condition: a systematic review and meta-analysis of prospective evidence.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 13 institutions in 1 country.

Agata CzarnowskaDepartment of Neurology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland.
Katarzyna Kapica-TopczewskaDepartment of Neurology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland.
Olga ZajkowskaFaculty of Economic Sciences, University of Warsaw, 00-241 Warszawa, Poland.ORCID 0000-0001-6520-1303
Monika Adamczyk-SowaDepartment of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.ORCID 0000-0002-6894-9891
Katarzyna Kubicka-BączykDepartment of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.
Natalia NiedzielaDepartment of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.ORCID 0000-0003-0834-5727
Paweł WarmusDepartment of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.
Alicja Kalinowska-ŁyszczarzDepartment of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
Karolina KaniaDepartment of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
Agnieszka SłowikDepartment of Neurology, Jagiellonian University Medical College, University Hospital, 30-688 Krakow, Poland.
Marcin WnukDepartment of Neurology, Jagiellonian University Medical College, University Hospital, 30-688 Krakow, Poland.
Monika MaronaDepartment of Neurology, Jagiellonian University Medical College, University Hospital, 30-688 Krakow, Poland.
Klaudia NowakDepartment of Neurology, Jagiellonian University Medical College, University Hospital, 30-688 Krakow, Poland.
Halina Bartosik-PsujekDepartment of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, 35-310 Rzeszów, Poland.ORCID 0000-0002-2860-6456
Beata LechNeurology Clinic with Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, 35-301 Rzeszów, Poland.
Adam PerencNeurology Clinic with Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, 35-301 Rzeszów, Poland.ORCID 0000-0001-8378-2340
Małgorzata PopielNeurology Clinic with Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, 35-301 Rzeszów, Poland.
Marta Kucharska-LipowskaDepartment of Neurology, Specialist Hospital in Końskie, 26-200 Końskie, Poland.
Monika ChorążyDepartment of Neurology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland.
Joanna TarasiukDepartment of Neurology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland.
Anna MirończukDepartment of Neurology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland.
Jan KochanowiczDepartment of Neurology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland.
Anetta Lasek-BalDepartment of Neurology, School of Health Sciences, Medical University of Silesia, 40-055 Katowice, Poland.
Przemysław PuzDepartment of Neurology, School of Health Sciences, Medical University of Silesia, 40-055 Katowice, Poland.
Katarzyna MaciejowskaDepartment of Neurology, School of Health Sciences, Medical University of Silesia, 40-055 Katowice, Poland.
Sławomir WawrzyniakDepartment of Neurology, 10th Military Research Hospital and Polyclinic, Independent Public Healthcare Centre, 85-681 Bydgoszcz, Poland.
Anna Niezgodzińska-MaciejekDepartment of Neurology, 10th Military Research Hospital and Polyclinic, Independent Public Healthcare Centre, 85-681 Bydgoszcz, Poland.
Anna Pokryszko-DraganDepartment of Neurology, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Ewa GruszkaDepartment of Neurology, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Sławomir BudrewiczDepartment of Neurology, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Marta BiałekDepartment of Neurology, Regional Specialised Hospital No. 4 in Bytom, 41-902 Bytom, Poland.
Jacek ZwiernikNeurology Ward, Provincial Specialist Hospital, 10-561 Olsztyn, Poland.
Anna MichałowskaNeurology Ward, Provincial Specialist Hospital, 10-561 Olsztyn, Poland.
Krzysztof NosekDepartment of Pharmacology and Toxicology, Faculty of Medicine, University of Warmia and Mazury, 10-719 Olsztyn, Poland.
Beata ZwiernikDepartment of Neurology, University of Warmia and Mazury, 10-719 Olsztyn, Poland.
Bożena LewańczykNeurology Ward, Provincial Integrated Hospital, 82-300 Elbląg, Poland.
Waldemar BrolaDepartment of Neurology, Specialist Hospital in Końskie, Collegium Medicum, Jan Kochanowski University Kielce, 26-200 Końskie, Poland.ORCID 0000-0002-7955-3454
Alina KułakowskaDepartment of Neurology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland.
Medical University of Białystok · PLMedical University of Silesia · PLJagiellonian University · PLUniversity of Rzeszów · PLUniversity of Warmia and Mazury in Olsztyn · PLWroclaw Medical University · PL1 Military Clinical Hospital with Outpatient Clinic · PLPoznan University of Medical Sciences · PLJan Kochanowski University · PLState University of Applied Sciences in Elbląg · PLState University of Applied Sciences in Konin · PLUniversity of Warsaw · PLWojewódzki Szpital Specjalistyczny nr 4 w Bytomiu · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: To report and analyze the presence of residual symptoms after SARS-CoV-2 infection among Polish patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). (2) Methods: The study included 426 individuals with MS treated with DMTs and confirmed SARS-CoV-2 infection from 12 Polish MS centers. The data were collected through to 31 May 2021. The information included demographics, specific MS characteristics, course of SARS-CoV-2 infection, and residual (general and neurological) symptoms lasting more than four and 12 weeks after the initial infection. The results were obtained using maximum likelihood estimates for odds ratio and logistic regression. (3) Results: A total of 44.84% patients with MS reported symptoms lasting between four and 12 weeks after the initial infection; 24.41% people had symptoms that resolved up to 12 weeks, and 20.42% patients had symptoms that lasted over 12 weeks. The most common symptoms were: fatigue, disturbance of concentration, attention, and memory, cognitive complaints, and headache. None of the DMTs were predisposed to the development of residual symptoms after the initial infection. A total of 11.97% of patients had relapse three months prior or after SARS-CoV-2 infection. (4) Conclusion: Almost half of individuals with MS treated with different DMTs had residual symptoms after SARS-CoV-2 infection. None of the DMTs raised the probability of developing post-acute COVID symptoms.

Indexed as

COVID-19disease modifying therapiesmultiple sclerosisresidual symptomsSARS-CoV-2

Identifiers

PMID34830507
PMCPMC8618380
OpenAlexW3212699244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.